4//SEC Filing
GRANDE ALICIA 4
Accession 0001161697-23-000610
CIK 0001369568other
Filed
Dec 11, 7:00 PM ET
Accepted
Dec 12, 5:00 PM ET
Size
17.6 KB
Accession
0001161697-23-000610
Insider Transaction Report
Form 4
GRANDE ALICIA
Chief Accounting Officer
Transactions
- Exercise/Conversion
Common stock, par value $0.001 per share
2023-12-08$1.13/sh+40,000$45,200→ 90,557 total - Sale
Common Stock, par value $0.001 per share
2023-12-08$14.30/sh−20,000$286,000→ 50,557 total - Sale
Common Stock, par value $0.001 per share
2023-12-11$13.74/sh−30,000$412,200→ 80,557 total - Exercise/Conversion
Options to purchase common stock
2023-12-08−40,000→ 1,255,834 totalExercise: $1.13Exp: 2024-01-03→ Common Stock (40,000 underlying) - Exercise/Conversion
Options to purchase common stock
2023-12-11−60,000→ 1,195,834 totalExercise: $1.13Exp: 2024-01-03→ Common Stock (60,000 underlying) - Sale
Common Stock, par value $0.001 per share
2023-12-08$14.25/sh−20,000$285,000→ 70,557 total - Exercise/Conversion
Common Stock, par value $0.001 per share
2023-12-11$1.13/sh+60,000$67,800→ 110,557 total - Sale
Common Stock, par value $0.001 per share
2023-12-11$13.79/sh−30,000$413,580→ 50,557 total
Footnotes (4)
- [F1]Ms. Grande sold the shares on the open market, for personal reasons, and to fund the exercise price and tax withholding of the exercise of the stock option, and not as a a result of any disagreement with the Company.
- [F2]Represents a weighted average price for the shares sold. Shares were sold in various lots ranging from $13.74 to $13.745 per share.
- [F3]Represents a weighted average price for the shares sold. Shares were sold in various lots ranging from $13.78 to $13.79 per share.
- [F4]Options vested in three annual tranches beginning on January 3, 2018.
Documents
Issuer
CATALYST PHARMACEUTICALS, INC.
CIK 0001369568
Entity typeother
Related Parties
1- filerCIK 0001402652
Filing Metadata
- Form type
- 4
- Filed
- Dec 11, 7:00 PM ET
- Accepted
- Dec 12, 5:00 PM ET
- Size
- 17.6 KB